Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CareDxSTU:1K9 68 Forward PE Ratio is 41.59 as of Sep. 04, 2026. GuruFocus rates STU:1K9 with a GF Score™ of 68/100 and a GF Value™ of €21.72 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 89 Medical Diagnostics & Research companies, CareDx ranks worse than 78.65% on this metric.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
CareDx Forward PE Ratio Related Terms
CareDx Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for CareDx's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CareDx Forward PE Ratio Chart
CareDx Annual Data
Trend
2018-12
2024-12
2025-12
Forward PE Ratio
2,500.00
36.99
21.88
CareDx Quarterly Data
2018-12
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
2026-06
Forward PE Ratio
2,500.00
36.99
29.07
30.73
18.39
21.88
24.36
31.07
STU:1K9 vs WGS, NEO, PSNL: Forward PE Ratio Comparison
For the Diagnostics & Research subindustry, CareDx's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CareDx Forward PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, CareDx's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where CareDx's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
CareDx (STU:1K9) has a Forward PE Ratio of 41.59 as of Sep. 04, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on CareDx and its competitors. According to the industry distribution chart, CareDx ranks #70 out of 89 companies in the Medical Diagnostics & Research industry, placing it in the top 78.7%.
Is CareDx's Forward PE Ratio too high?
CareDx's current Forward PE Ratio is 41.59. The Medical Diagnostics & Research industry median Forward PE Ratio is 21.34. CareDx's value of 41.59 is 94.9% above this industry median. Based on the distribution chart, CareDx ranks #70 out of 89 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, CareDx has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CareDx's Forward PE Ratio compare to WGS and NEO?
According to the Medical Diagnostics & Research industry distribution chart, CareDx ranks #70 out of 89 companies for Forward PE Ratio. This places CareDx in the lower half of its industry. The industry median Forward PE Ratio is 21.34. CareDx's value of 41.59 is 94.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Diagnostics & Research company?
The median Forward PE Ratio among Medical Diagnostics & Research companies is 21.34, based on 89 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CareDx's current Forward PE Ratio of 41.59 is 94.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on CareDx and its competitors. For the Medical Diagnostics & Research industry, the median Forward PE Ratio is 21.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CareDx's current Forward PE Ratio is 41.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CareDx stock overvalued right now?
Based on GuruFocus' analysis, CareDx (STU:1K9) is currently considered Significantly Overvalued. The stock's GF Value™ is €21.72, compared to a current price of €42.80 — trading 97.1% above its estimated fair value. The current Forward PE Ratio is 41.59 and 94.9% above the Medical Diagnostics & Research industry median of 21.34. CareDx's overall GF Score™ is 68/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For CareDx (STU:1K9), the current Forward PE Ratio is 41.59 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CareDx (STU:1K9) Overvalued in 2026?
Based on GuruFocus' analysis, CareDx stock appears to be overvalued.
The current stock price of €42.80 is trading 97.1% above its estimated GF Value™ of €21.72.
GuruFocus considers CareDx to be Significantly Overvalued.
Key valuation signals for STU:1K9:
Forward PE Ratio: 41.59
GF Value™: €21.72 vs. price of €42.80 (97.1% above fair value)
Industry Position: 94.9% above the Medical Diagnostics & Research median (#70 of 89)
No single metric tells the full story. See the STU:1K9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
68GF Score
Get the complete analysis for STU:1K9
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1K9 has been successfully added to your 
